Compare Ginkgo Bioworks Holdings Inc (DNA) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Nokia Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M), while Nokia Corp trades at $10.4 (market cap $53.00B). The key difference: Nokia Corp is far larger — about 104.8× Ginkgo Bioworks Holdings Inc's market cap, and Nokia Corp pays a 1.73% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | NOK | |
|---|---|---|
Market Cap | $505.73M | $53.00B |
Sector | Health | Technology |
52-Week High | $16.14 | $16.83 |
52-Week Low | $5.48 | $4.13 |
Enterprise Value | $607.68M | $50.95B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Nokia (NOK) trades at $9.12, down 2.67% today amid a bearish technical signal, with mixed earnings performance including a Q2 2026 EPS beat. Revenue has stabilized near $20B annually, but net margins are thin at 3.47%. The company is pivoting toward AI and cloud infrastructure, with recent news highlighting demand growth in these areas. Cash flow turned negative in 2025, though the balance sheet remains solid with $8.91B in cash.
Outlook is cautiously optimistic due to AI-driven demand and insider buying, but risks include telecom spending volatility and high P/E valuation. Analyst consensus is bullish with 60% buy ratings. The stock faces near-term pressure from technical indicators but offers long-term potential if AI initiatives accelerate growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
